Session: 203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Poster II
Hematology Disease Topics & Pathways:
Education, Diseases, Immune Disorders, Immunodeficiency, Immunology, Biological Processes
We retrospectively analyzed 512 NTM-PD patients diagnosed over a decade (2013–2023). Patients were identified via ICD-10 codes and validated through detailed medical record review, extracting 42 variables. The cohort was divided into immunoglobulin-deficient and non-deficient groups. The primary endpoint was all-cause mortality. Multivariate regression modeling, adjusting for confounders like age, sex, race, comorbidities, and treatments, was used to identify mortality risk factors.
Our analysis revealed a significant association between immunodeficiency and increased mortality (AOR: 3.56, 95% CI: 1.874-6.790, P=0.0001), indicating that immunoglobulin-deficient patients with NTM-PD had a 256% higher risk of death compared to those without immunodeficiency. Chronic Obstructive Pulmonary Disease (COPD) was another significant predictor of mortality (AOR: 1.91, 95% CI: 1.202-3.047, P=0.006), suggesting that patients with COPD had a 91% higher risk of mortality. Anemia also increased the mortality risk (AOR: 1.65, 95% CI: 1.052-2.542, P=0.029), indicating a 65% higher risk. Heart failure showed a borderline statistical significance (AOR: 1.64, 95% CI: 0.967-2.810, P=0.06), which implies a potential 64% higher risk of mortality, though this result was not conclusive.
The comorbidities that increase the risk of NTM-PD such as bronchiectasis (AOR: 1.07, 95% CI: 0.706-1.641, P=0.731), diabetes mellitus (AOR: 1.53, 95% CI: 0.851-2.716, P=0.155), chronic kidney disease (AOR: 1.44, 95% CI: 0.903-2.297, P=0.125), Obesity (AOR: 1.00, 95% CI: 0.999-1.090, P=0.63), and smoking status (AOR: 1.02, 95% CI: 0.633-1.663, P=0.916) were not statistically significant predictors.
Our study underscores the significant impact of immunoglobulin deficiencies in NTM-PD patients mortality outcome, highlighting the need for targeted management strategies. Immunoglobulin-deficient patients exhibit a markedly higher mortality risk, and addressing these immunological deficiencies could improve outcomes in this population. COPD and anemia were also critical predictors of mortality. The findings suggest that comprehensive management approaches, particularly in patients with these comorbidities, are essential. Further research with larger sample sizes is warranted to validate these findings and develop effective treatment strategies for improving outcomes in NTM-PD patients.
Disclosures: No relevant conflicts of interest to declare.
See more of: Oral and Poster Abstracts